Literature DB >> 9797254

Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

J V Brooks1, I M Orme.   

Abstract

Once-weekly therapy with combinations of isoniazid plus a rifamycin was tested in the mouse low-dose aerosol infection model against two strains of Mycobacterium tuberculosis. Combinations of isoniazid and rifalizil and isoniazid and rifapentine were both highly effective. These animal model data thus support the evaluation of these regimens under clinical conditions.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9797254      PMCID： PMC105994     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

Authors:  D L Cohn; B J Catlin; K L Peterson; F N Judson; J A Sbarbaro
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

2.  An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis.

Authors:  S E Valway; M P Sanchez; T F Shinnick; I Orme; T Agerton; D Hoy; J S Jones; H Westmoreland; I M Onorato
Journal:  N Engl J Med       Date:  1998-03-05       Impact factor: 91.245

3.  Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M A Flory
Journal:  Am Rev Respir Dis       Date:  1990-03

4.  Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection).

Authors:  S Pretet; A Lebeaut; R Parrot; C Truffot; J Grosset; A T Dinh-Xuan
Journal:  Eur Respir J       Date:  1992-06       Impact factor: 16.671

5.  Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.

Authors:  B Ji; C Truffot-Pernot; C Lacroix; M C Raviglione; R J O'Brien; P Olliaro; G Roscigno; J Grosset
Journal:  Am Rev Respir Dis       Date:  1993-12

6.  Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.

Authors:  J Dhillon; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1992-01

7.  Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.

Authors:  D Jabès; C Della Bruna; R Rossi; P Olliaro
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.

Authors:  S P Klemens; M A Grossi; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-09

10.  Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

Authors:  L Chapuis; B Ji; C Truffot-Pernot; R J O'Brien; M C Raviglione; J H Grosset
Journal:  Am J Respir Crit Care Med       Date:  1994-11       Impact factor: 21.405
View more
  10 in total

1.  Search for new drugs for treatment of tuberculosis.

Authors:  I Orme
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Authors:  N Veziris; N Lounis; A Chauffour; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Authors:  A M Lenaerts; S E Chase; A J Chmielewski; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.

Authors:  C M Shoen; S E Chase; M S DeStefano; T S Harpster; A J Chmielewski; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

6.  Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Authors:  Anne J Lenaerts; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Diane K Driscoll; Nicholas M Tompkins; Jerry D Rose; Robert C Reynolds; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.

Authors:  A M Lenaerts; S E Chase; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Authors:  Tianyu Zhang; Ming Zhang; Ian M Rosenthal; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

10.  Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.

Authors:  Donald R Hoff; Gavin J Ryan; Emily R Driver; Cornelius C Ssemakulu; Mary A De Groote; Randall J Basaraba; Anne J Lenaerts
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.